Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Priority review period for Novartis cancer drug extended
Priority review period for Novartis cancer drug extended
Priority review period for Novartis cancer drug extended
Submitted by
admin
on November 25, 2014 - 9:57am
Source:
Seeking Alpha
News Tags:
Novartis
Multiple Myeloma
panobinostat
bortezomib
Headline:
Priority review period for Novartis cancer drug extended
Do Not Allow Advertisers to Use My Personal information
